Latest Commercialization News

Ora Banda Mining Ltd delivered a standout FY25 with net profit soaring 575% to $186 million, driven by record gold production and successful underground mine expansions. The company sets ambitious FY26 targets amid strong operational momentum.

Imricor Medical Systems reports significant regulatory approvals and clinical trial progress, positioning itself as a disruptive force in the growing electrophysiology market. With a strengthened commercial pipeline and solid cash reserves, the company is poised for a pivotal growth phase.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

Pointerra Limited reported a strong FY25 with revenue up 45% to A$11 million and a significant reduction in net loss by 68%, driven by scalable SaaS growth and key US contract wins.

AUB Group has reported a robust FY25 with a 17% rise in underlying net profit after tax and increased dividends, setting an optimistic tone for FY26 with growth guidance up to 13.4%.

Unibail-Rodamco-Westfield has requested suspension of its securities from the ASX, marking the first step toward its official delisting. This move signals a significant shift for investors and the commercial property sector.

Acrow Limited reports a record FY25 with sales up 23%, driven by an 83% jump in its Industrial Access division, now half of group revenue. Despite soft formwork markets, strategic acquisitions and growth initiatives underpin a confident outlook.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Symal Group has outperformed its FY25 earnings forecasts, driven by strong project margins and strategic acquisitions, setting a robust foundation for FY26 growth.

Embelton Limited reports a notable decline in revenue and profit for FY2025 amid a challenging construction market, yet maintains its dividend payout, signaling cautious optimism.

Desane Group Holdings Limited reported a strong FY25 with net profit after tax doubling to $3.3 million, supported by a $6.2 million uplift in property valuations and key lease extensions securing future rental income.